Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FY 2021 Appropriations Provides FDA Healthy Boost – Plus More COVID-19 Funds

Executive Summary

Budget authority increase for medical product safety is coupled with additional funds for coronavirus countermeasure development and advanced manufacturing.

You may also be interested in...



US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.

Congress Already Preparing For User Fee Bills

Multiple congressional offices attended a briefing on GDUFA III with FDA and industry officials, suggesting plans for the must-pass bill already are in the works.

US FDA COVID Funds Move Forward In Congress, No Strings Attached

Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel